Manufactures aliphatic amines and acetonitrile, selling to pharmaceutical and agrochemical customers from three manufacturing sites. FY26 revenue was ₹1,535.85 crore with an EBITDA margin of 20.6%. Products fall into methylamines (a four-player domestic market after Aarti's entry), ethylamines (a stable duopoly with Balaji) and acetonitrile (where an anti-dumping duty has been approved by the Ministry of Finance). End-market exposure is roughly 55-60% pharma and 15-20% agro, with the remainder spread across other specialty chemical uses. The single largest cost is raw materials (51.5% of revenue), with ammonia — sourced externally — being the key input whose price doubled to over ₹100/kg during FY26. A new product is scheduled to launch in July 2026 from the Dahej plant, and the Kurkumbh project is mechanically complete, with commissioning pushed to early Q1 FY27. FY27-FY28 capex has been guided at ₹80-90 crore, focused on Dahej completion and maintenance. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Methylamines, Ethylamines, Acetonitrile, Other specialty amines / new products. Specialty chemicals manufacturer; aliphatic amines (methylamines, ethylamines) and acetonitrile, asset-light by chemicals standards but exposed to raw-material and capacity-cycle swings.
| ₹ crore · consolidated | FY19 | FY20 |
|---|---|---|
| Revenue | 846 | 993 |
| EBITDA (ex other income) | 164 | 272 |
| margin % | 19.4 | 27.4 |
| Owners' profit | 0 | 0 |
| EPS, as reported (₹) | 40.26 | 98.71 |
| ROE % · ROCE % | 22.7 · 27.8 | 37.5 · 40.0 |
| Debt / equity (x) | 0.34 | 0.09 |
| Cash from operations | — | — |
| Capex | — | — |
| ₹ crore | Q4 FY19 | Q2 FY20 | Q3 FY20 | Q4 FY20 |
|---|---|---|---|---|
| Revenue | 237 | 235 | 257 | 235 |
| Profit before tax | 30 | 49 | 81 | 61 |
| Net profit | 18 | 55 | 60 | 49 |
| EPS (₹) | 8.61 | 26.93 | 29.62 | 24.13 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| PIDILITE INDUSTRIES LTD | 1,59,479 | 60.2 | 14.43 | 42.3 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 73,583 | 34.0 | 5.24 | 22.7 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 52,514 | 85.7 | 6.64 | 41.5 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,836 | 55.4 | 11.03 | 39.5 | 16.7 | 16.4 | 23.0 | 37.5 |
| AETHER INDUSTRIES LIMITED | 22,229 | 94.3 | 9.05 | 60.4 | 8.9 | 11.4 | — | 33.8 |
| DEEPAK NITRITE LTD | 21,769 | 27.8 | 3.71 | 22.4 | 9.4 | 10.2 | 12.6 | 21.5 |
| ATUL LTD |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 19 Aug 2026 · Newspaper publication of Postal Ballot notice | compliance | minimal | — | — |
| 18 Aug 2026 · Postal Ballot: Re-designation of 4 directors, NED commission approval | board shareholder meetings | low | — | — |
| 4 Aug 2026 · Alkyl Amines Q1 PAT up 91% YoY at Rs 94.63 Cr; director re-designations approved | results | high | — | — |
| 4 Aug 2026 · Alkyl Amines Q1 FY27 PAT up 91% YoY at Rs 94.6 Cr; leadership rejig | results | high | — | — |
| 4 Aug 2026 · Alkyl Amines Q1 FY27 PAT jumps 91% YoY; top management re-designated | results | high | — | — |
| 29 Jul 2026 · Newspaper notice on physical share transfer re-lodgement window | compliance | minimal | — | — |
| 17 Jul 2026 · Board meeting on Aug 4, 2026 to consider Q1 FY27 financial results | results | low | — | — |
| 7 Jul 2026 · 46th AGM results: all 4 resolutions passed, Rs 10 per share dividend approved | board shareholder meetings | medium | — | — |
| 7 Jul 2026 · Routine SEBI compliance certificate for Q1 FY27 dematerialization | compliance | minimal | — | — |
| 3 Jul 2026 · Alkyl Amines 46th AGM: Dividend, Capex Plans, Anti-Dumping Duty Win | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 18,401 |
| 23.1 |
| 2.92 |
| 14.9 |
| 10.9 |
| 13.3 |
| 10.9 |
| 23.1 |
| AARTI INDUSTRIES LTD | 17,846 | 33.6 | 3.00 | 18.8 | 7.0 | 4.4 | 13.0 | 16.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 20.9 | 23.4 | 44 of 103 | 58% |
| P/B | 17.8 | 2.9 | 97 of 99 | 2% |
| ROCE | 38.3 | 10.3 | 3 of 108 | 98% |
| ROE | 37.5 | 8.1 | 2 of 101 | 99% |
| Debt / Equity | 0.1 | 0.2 | 44 of 101 | 57% |
| EBITDA margin | 29.9 | 15.5 | 10 of 99 | 91% |
| Market cap | 9529 | 732 | 17 of 107 | 85% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
